SUMMIT
BIOANALYTICS
Certificate of Analysis
#SBA-26-0003
Summit BioAnalytics | Nassau, The Bahamas | lab@summitbioanalytics.com | summitbioanalytics.com
Tested for
Northgate Peptide Co.
www.example-northgate.test
Sample
Tirzepatide — 10 mg
Batch #
NPC-0719
Purity
94.20%
Mass
9.41 mg
Identity
Confirmed
- COA #:
- SBA-26-0003
- Lot Number:
- NPC-0719
- Labeled Content:
- 10 mg
- Method:
- Purity & Quant (HPLC)
- Analysis Date:
- 2026-07-24
- Date Received:
- 2026-07-22
- Appearance:
- White lyophilized powder, slight cake collapse
Scan to verify
Identity
Purity
Endotoxins— not tested
Fentanyl Free
| Test | Specification | Result |
|---|---|---|
| Identity | Tirzepatide | Confirmed |
| Purity (HPLC) | >= 98.0% | 94.20%Out of spec |
| Quantity | 10.0 mg ± 10% | 9.41 mg |
| Fentanyl Screen (LC-MS/MS) | Not detected | Not detected |
Qualitative and quantitative chemical analysis by RP-HPLC with UV detection; identity confirmed by LC-MS. Fentanyl screening by targeted LC-MS/MS. Full methodology available on request.
Tirzepatide (10 mg) — UV 214 nm
HPLC Chromatogram · MS observed 4813.2 Da, theoretical 4813.5 Da
| Peak | RT (min) | Area % |
|---|---|---|
| Solvent front | 1.8 | 0.40 |
| Impurity A | 7.2 | 2.90 |
| Tirzepatide | 10.9 | 94.20 |
| Impurity B | 13.6 | 1.80 |
| Impurity C | 16.1 | 0.70 |
Kasey MalganiusSigned by Kasey Malganius, Lab Director
Kasey Malganius
Lab Director
2026-07-24
- COA #:
- SBA-26-0003
- Access Code:
- T2JH8V5D
- Analyst:
- R. Whitfield
- Verify:
- summitbioanalytics.com/verify
- Issued:
- 2026-07-24